APLS — курсы расширенных реанимационных мероприятий в педиатрии, спонсируемые Американской академией педиатрии и Американской коллегией врачей неотложной помощи (Advanced Pediatric Life Support)
AVPU — шкала для оценки уровня сознания («в ясном сознании»; «реакция на вербальные раздражители»; «реакция на боль»; «без сознания») (alert, verbal, pain, unresponsive)
CADASIL — церебральная аутосомно-доминантная артериопатия с подкорковыми инфарктами и лейкоэнцефалопатией (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)
DSM — Диагностическое и статистическое руководство по психическим расстройствам (Diagnostic and Statistical Manual of Mental Disorders)
EAST syndrome — эпилепсия, атаксия, сенсоневральная тугоухость и тубулопатия (epilepsy, ataxia, sensorineural hearing loss, and tubulopath)
EBM — доказательная медицина (evidance based medicine)
EPCAM — молекула адгезии эпителиальных клеток (epithelial cell adhesion molecule)
ESC — Европейское общество кардиологии (European Society of Cardiology)
EXIT — лечение плода вне матки во время родов (ех utero intrapartum treatment)
FcRs — Fc-рецепторы — белок, расположенный на поверхности нескольких видов клеток иммунной системы (естественных киллеров, макрофагов, нейтрофилов и тучных клеток) FDA — Комитет по контролю за лекарственными веществами и пищевыми добавками, США (Food and Drug Administration)
MELAS — митохондриальная энцефалопатия, лактоацидоз и инсультоподобные эпизоды (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes)
MELD — модель для оценки терминальной стадии заболеваний печени, предназначена для оценки относительной тяжести заболевания и прогноза жизни у пациентов с терминальной стадией печеночной недостаточности (ожидающих трансплантации печени) (model for end-stage liver disease)
MERRF — миоклоническая эпилепсия с рваными красными волокнами (myoclonic epilepsy with ragged red fibers)
MHC — главный комплекс гистосовместимости (major histocompatibility complex)
Mr — кажущаяся молекулярная масса
MRP — белок с множественной лекарственной устойчивостью (multidrug-resistant protein)
mTOR — мишень рапамицина у млекопитающих (mammalian target of rapamycin)
NB! — важно, обратить внимание (nota bene)
NICE — Национальный институт здоровья и клинического совершенствования (качества медицинской помощи) Великобритании (National Institute for Health and Clinical Excellence)
NK — естественные клетки-киллеры (natural killer) NMDA — И-метил-В-аспартат (N-methyl-D-aspartate)
NNT — число больных, которых необходимо пролечить, чтобы достичь какого-то указанного эффекта (number need to treatment)
OR — отношение шансов (odds ratio)
paCO2 — парциальное давление углекислого газа в артериальной крови
PALS — курсы расширенных реанимационных мероприятий в педиатрии (Pediatric Advanced Life Support)
PANDAS — аутоиммунное нейропсихиатрическое расстройство в детском возрасте, ассоциированное со стрептококковой инфекцией (pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
PANS — острый нейропсихиатрический синдром в детском возрасте (pediatric acute-onset neuropsychiatric syndrome)
paO2 — парциальное давление кислорода в артериальной крови
PAS — фуксинсернистая кислота, реактив Шиффа (periodic acid-Shiff)
PC — после еды (при назначениях) (post cibum) рСО2 — парциальное давление углекислого газа
PCSK-9 — пропротеиновая конвертаза субтилизинкексинового типа 9 (proprotein convertase subtilisin/kexin type 9)
PFAPA — периодическая лихорадка с афтозным стоматитом, фарингитом и лимфаденитом (periodic fevers with aphthous stomatitis, pharyngitis and adenitis)
PIM — показатель летального исхода у детей (pediatric index of mortality)
piO2 — парциальное давление кислорода во вдыхаемом воздухе
рО2 — парциальное давление кислорода
POLG — субъединица ДНК-полимеразы γ
PRISA II — оценка риска госпитализации у детей II (pediatric risk of admission)
PRISM — риск летального исхода у детей (pediatric risk of mortality)
PRN — при (по) необходимости (pro re nata — при возникновении обстоятельств)
PRSS — ген сериновой протеазы
PS — примечание (post scriptum)
PUVA-терапия — псорален-ультрафиолет А-терапия (psoralen and ultraviolet А)
Q#H — каждые # часов (при назначениях) (quaque... hora)
QAM — каждое утро (при назначениях) (quaque ante meridiem)
QPM — каждый вечер (при назначениях) (quaque post meridiem)
RAG — ген, активирующий рекомбиназу
RePEAT — пересмотренный инструмент для оценки педиатрической неотложной медицинской помощи (Revised Pediatric Emergency Assessment Tool)
RF — ревматоидный фактор
Rh — резус(-фактор)
Rh«-» — резус-отрицательн(ый)
Rh«+» — резус-положительн(ый)
ROHHAD — быстро развивающееся ожирение с дисфункцией гипоталамуса, гиповентиляцией и спонтанной дисрегуляцией (rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation)
αDG-RD — дистрофии, связанные с α-дистрогликанами (alpha dystroglycan-related dystrophies)
β-ХГЧ — β-субъединица хорионического гонадотропина человека
В ходе подготовки статей по болезням обмена веществ в терапии для пользователей сайта МедУнивер использованы труды следующих авторов:
Thomas J, Levy H, Amato S, et al. Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM). Mol Genet Metab. 2018;124:27–38.
Harding CO, Amato RS, Stuy M, etal. Pegvaliase for the treatment of phenylketonuria: a pivotal, double-blind randomized discontinuation phase 3 clinical trial. Mol Genet Metab. 2018;124:20–26.
Saudubray JM, Mochel F. The phenotype of adult versus pediatric patients with inborn errors of metabolism. J Inherit Metab Dis. 2018;41:753–756.
Navarrete R, Leal F, Vega AI, et al. Value of genetic analysis for confirming inborn errors of metabolism detected through the Spanish neonatal screening program. Eur J Hum Genet. 2019;27:556–562.
Ferreira CR, van Karnebeek CDM, Vockley J, et al. A proposed nosology of inborn errors of metabolism. Genet Med. 2019;21:102–106.
Lichter-Konecki U, Vockley J. Phenylketonuria: current treatments and future developments. Drugs. 2019;79(5):495–500.
Aliu E, Kanungo S, Arnold GL. Amino acid disorders. Ann Transl Med. 2018;6:1–10.
Waisbren SE, Gropman AL, Batshaw ML, et al. Improving long-term outcomes in urea cycle disorders-report from the urea cycle disorders consortium. J Inherit Metab Dis. 2016;39:573–584.
Bellattato CM, Hubert L, Scarpa M, et al. Inborn errors of metabolism involving complex molecules: lysosomal and peroxisomal storage diseases. Pediatr Clin North Am. 2018;65:353–373.
Yubero D, Brandi N, Ormazabal A, et al. Targeted next generation sequencing in patients with inborn errors of metabolism. PLoS ONE. 2016;11:1–10.
Wang W, Yang J, Xue J, et al. A comprehensive multiplex PCR based exome-sequencing assay for rapid bloodspot confirmation of inborn errors of metabolism. BMC Med Genet. 2019;20:1–14.
Smets F, Dobbelaere D, McKiernan P, et al. Phase I/II trial of liver derived mesenchymal stem cells in pediatric liver based metabolic disorders: a prospective, open label, multicenter, partially randomized, safety study of one cycle of heterologous human adult liver-derived progenitor cells (HepaStem®) in urea cycle disorders and Crigler-Najjar syndrome patients. Transplantation. 2019;103(9):1903–1915.
van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12:162.
Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–1405.
Sabatine MS, Wiviott SD, Im K, et al. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis. JAMA Cardiol. 2018;3:823–828.
Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39:1172–1180.
Mills EJ, O’Regan C, Eyawo O, et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur Heart J. 2011;32: 1409–1415.
Chou R, Dana T, Blazina I, et al. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316: 2008–2024.
Bowman L, Hopewell JC, Chen F, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217–1227.
Zhan S, Tang M, Liu F, et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018;11:CD012502.
Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–1509.
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–2107.
Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289–1297.
Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
Cholesterol Treatment Center Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393:407–415.
He Y, Li X, Gasevic D, et al. Statins and multiple noncardiovascular outcomes: umbrella review of meta-analyses of observational studies and randomized controlled trials. Ann Intern Med. 2018; 169:543–553.
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390:1962–1971.
Steg PG, Szarek M, Bhatt DL, et al. Effect of alirocumab on mortality after acute coronary syndromes: an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation. 2019;140(2):103–112.
Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018;319:1566–1579.
Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
Probstfield JL, Boden WE, Anderson T, et al. Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort. J Clin Lipidol. 2018;12:1413–1419.
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–1291.
Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380:23–32.
Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
Carroll MD, Fryar CD, Nguyen DT. Total and high-density lipoprotein cholesterol in adults: United States, 2015–2016. NCHS Data Brief. 2017;1–8.
Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics–2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–e528.
Robinson JG, Williams KJ, Gidding S, et al. Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein B lipoproteins earlier in life. J Am Heart Assoc. 2018;7:1–12.
Hawley CE, Roefaro J, Forman DE, et al. Statins for primary prevention in those aged 70 years and older: a critical review of recent cholesterol guidelines. Drugs Aging. 2019;36(8):687–699.
Ference BA, Kastelein JJP, Ginsberg HN, et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA. 2017;318:947–956.
Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375:2144–2153.
Gidding SS, Ann Champagne M, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132:2167–2192.
Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1736–1788.
Madsen CM, Varbo A, Nordestgaard BG. Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study. Eur Heart J. 2018;39:610–619.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary. Circulation. 2019;139:e1046–e1081.
Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;316:1997–2007.
Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2019;73:3153–3167.
Robinson JG, Huijgen R, Ray K, et al. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol. 2016;68:2412–2421.
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140(11):e596–646.
Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence — focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39:2526–2539.
Robinson JG, Jayanna MB, Brown AS, et al. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit: a statement from the National Lipid Association. J Clin Lipidol. 2019;13(4):525–537.
Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321:364–373.
Fan W, Philip S, Granowitz C, et al. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. J Clin Lipidol. 2019;13:100–108.
Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72:330–343.
Kanungo S, Wells K, Tribett T, et al. Glycogen metabolism and glycogen storage disorders. Ann Transl Med. 2018;6:1–8.
Weinstein DA, Steuerwald U, De Souza CFM, et al. Inborn errors of metabolism with hypoglycemia: glycogen storage diseases and inherited disorders of gluconeogenesis. Pediatr Clin North Am. 2018;65:247–265.
Ross KM, Brown LM, Corrado MM, et al. Safety and efficacy of chronic extended release cornstarch therapy for glycogen storage diseases type I. JIMD Rep. 2016;26:85–90.
Dale DC, Bolyard AA, Marrero T, et al. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. Curr Opin Hematol. 2019;26:16–21.
Melis D, Minopoli G, Balivo F, et al. Vitamin E improves clinical outcome of patients with glycogen storage disease type Ib. JIMD Rep. 2016;25:39–45.
Dambska M, Labrador E, Kuo CL, et al. Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control. Pediatr Diabetes. 2017;18:327–331.
Sentner CP, Hoogeveen IJ, Weinstein DA, et al. Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. J Inherit Metab Dis. 2016;39:697–704.
Mistry PK, Lukina E, Ben Turkia H, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015;313:695–706.
Mistry PK, Lukina E, Ben Turkia H, et al. Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: the phase 3 ENGAGE trial. Am J Hematol. 2017;92: 1170–1176.
El Dib RP, Nascimento P, Pastores GM. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2013;2:CD006663.
Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomized phase III ATTRACT study. J Med Genet. 2017;54:288–296.
Burton BK, Balwani M, Feillet F, et al. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med. 2015;373:1010–1020.
Sun A. Lysosomal storage disease overview. Ann Transl Med. 2018;6:1–14.
Ries M. Enzyme replacement therapy and beyond—in memoriam Roscoe O. Brady (1923–2016). J Inherit Metab Dis. 2017;40:343–356.
Nalysnyk L, Rotella P, Simeone JC, et al. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017;22:65–73.
Lukina E, Watman N, Dragosky M, et al. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: final results from the phase 2 trial. Am J Hematol. 2019;94:29–38.
Arends M, K?rver S, Hughes DA, et al. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis. 2018;41:141–149.
Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet. 2016;388:476–487.
Ory DS, Ottinger EA, Farhat NY, et al. Intrathecal 2-hydroxypropyl-beta-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet. 2017;390:1758–1768.
Schulz A, Ajayi T, Specchio N, et al. Study of intraventricular cerliponase alfa for CLN2 DISEASE. N Engl J Med. 2018;378:1898–1907.
Valayannopoulos V, Mengel E, Brassier A, Grabowski G. Lysosomal acid lipase deficiency: expanding differential diagnosis. Mol Genet Metab. 2017;120:62–68.
Pericleous M, Kelly C, Wang T, et al. Wolman’s disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency. Lancet Gastroenterol Hepatol. 2017;9:670–679.
Muenzer J, Jones SA, Tylki-Szyma?ska A, et al. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2017;12:1–9.
Mitchell J, Berger K, Borgo A, et al. Unique medical issues in adult patients with mucopolysaccharideoses. EJIM. 2016;34:2–10.
Mistry PK, Lukina E, Ben Turkia H, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015;313:695–706.
Mistry PK, Lukina E, Ben Turkia H, et al. Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: the phase 3 ENGAGE trial. Am J Hematol. 2017;92: 1170–1176.
El Dib RP, Nascimento P, Pastores GM. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2013;2:CD006663.
Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomized phase III ATTRACT study. J Med Genet. 2017;54:288–296.
Burton BK, Balwani M, Feillet F, et al. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med. 2015;373:1010–1020.
Kumar A, Palfrey HA, Pathak R , et al. The metabolism and significance of homocystelne in nutrition and health. Nutr Metab (Lond). 2017;14:1–12.
Morris AA, Ko?ich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis. 2017;40:49–74.
Kruger WD. Cystathionine ?-synthase deficiency: of mice and men. Mol Genet Metab. 2017;121:199–205.
Ospina-Romero M, Cannegieter SC, den Heijer M, et al. Hyperhomocysteinemia and risk of first venous thrombosis: the influence of (unmeasured) confounding factors. Am J Epidemiol. 2018;187:1392–1400.
Almuqbil MA, Waisbren SE, Levy HL, et al. Revising the psychiatric phenotype of homocystinuria. Genet Med. 2019;21(8):1827–1831.
Huemer M, Diodato D, Schwahn B, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017;40:21–48.
Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373:48-59.
Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017;377:862–872.
Yien YY, Ducamp S, van der Vorm LN, et al. Mutation in human CLPX elevates levels of delta-aminolevulinate synthase and protoporphyrin IX to promote erythropoietic protoporphyria. Proc Natl Acad Sci USA. 2017;114:E8045–E8052.
Chen B, Solis-Villa C, Hakenberg J, et al. Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease. Hum Mutat. 2016;37:1215–1222.
Manceau H, Gouya L, Pug H. Acute hepatic and erythropoietic porphyrias: from ALA synthases 1 and 2 to new molecular bases and treatments. Curr Opin Hematol. 2017;24:198–207.
Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. Br J Haematol. 2016;176:527–538.
Yasuda M, Chen B, Desnick RJ. Recent advances on porphyria genetics: inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes. Mol Genet Metab. 2019;128(3):320–331.
Di Pierro E, Brancaleoni V, Granata F. Advances in understanding the pathogenesis of congenital erythropoietic porphyria. Br J Haematol. 2016;173:365–379.
Balwani M, Wang B, Anderson KE, et al. Acute hepatic porphyrias: recommendations for evaluation and long-term management. Hepatology. 2017;66:1314–1322.
Naik H, Stoecker M, Sanderson SC, et al. Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: a qualitative study. Mol Genet Metab. 2016;119:278–283.
Tchernitchko D, Tavernier Q, Lamoril J, et al. A variant of Peptide Transporter Two predicts the severity of porphyria associated kidney disease will stop. J Am Soc Nephrol. 2017;28:1924–1932.
Kevelam SH, Neeleman RA, Waisfisz Q, et al. Acute intermittent porphyria-related leukoencephalopathy. Neurology. 2016;87:1258–1265.
Woolf J, Marsden JT, Degg T, et al. Best practice guidelines on first-line laboratory testing for porphyria. Ann Clin Biochem. 2017;54:188–198.
Sardh E, Harper P, Balwani M, et al. Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med. 2019;380:549–558.
Schulenburg-Brand D, Gardiner T, Guppy S, et al. An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the United Kingdom. JIMD Rep. 2017;36:99–107.
Minder EI, Barman-Aksozen J. Iron and erythropoietic porphyrias. Blood. 2015;126:130–132.
Weiss KH, Askari FH, Czlonkowska A, et al. Phase 2 study of WTX101 (bis-choline tetrathiomolybdate) in patients with Wilson disease. Lancet. 2017;2:869–876.
Lalioti V, Tsubota A, Sandoval IV. Disorders in hepatic copper secretion: Wilson’s disease and pleomorphic syndromes. Semin Liver Dis. 2017;37:175–185.
Pierson H, Muchenditsi A, Kim BE, et al. The function of ATPase copper transporter ATP7B in intestine. Gastroenterology. 2018;153:168–180.
Gerosa C, Fanni D, Congiu T, et al. Liver pathology in Wilson’s disease: from copper overload to cirrhosis. J Inorg Biochem. 2019;193:106–111.
Shribman S, Warner TT, Dooley JS. Clinical presentations of Wilson disease. Ann Transl Med. 2019;7(Suppl 2):S60,1–15.
Poujois A. Woimant F. Wilson’s disease: a 2017 update. Clin Res Hepatol Gastroenterol. 2018;42:512–520.
Boga S, Ala A, Schilsky ML. Hepatic features of Wilson disease. Handb Clin Neurol. 2017;142:91–99.
Czoonkowska A, Litwin T, Chabik G. Wilson disease: neurologic features. Handb Clin Neurol. 2017;142:101–119.
Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet Neurol. 2015;14:103–113.
Biswas S, Paul N, Das SK. Nonmotor manifestations of Wilson’s disease. Int Rev Neurobiol. 2017;134:1443–1459.
Hefter H, Tezeyak O, Rosenthal D. Long-term outcomes of neurological Wilson’s disease. Parkinsonism Relat Disord. 2018;49:48–53.
Litwin T, Duskek P, Szafranski T, et al. Psychiatric manifestations in Wilson’s disease: possibilities and difficulties for treatment. Ther Adv Psychopharmacol. 2018;8:199–211.
Bose S, Sonny A, Rahman N. A teenager presents with fulminant hepatic failure and acute hemolytic anemia. Chest. 2015;147:e100–e104.
Ferenci P. Diagnosis of Wilson disease. Handb Clin Neurol. 2017;142:171–180.
Schonfeld EA, Brown RS Jr. Genetic testing in liver disease: what to order, in whom, and when. Clin Liver Dis. 2017;21:673–686.
Horn N, Moller LB, Nurchi VM, et al. Chelating principles in Menkes and Wilson diseases: choosing the right compounds in the right combinations at the right time. J Inorg Biochem. 2019;190:98–112.
Hedera P. Update on the clinical management of Wilson’s disease. Appl Clin Genet. 2017;10:9–19.
Kathawala M, Hirschfield GM. Insights into the management of Wilson’s disease. Therap Adv Gastroenterol. 2017;10:889–905.
Schilsky ML. Wilson disease: diagnosis, treatment, and follow-up. Clin Liver Dis. 2017;21:755–767.
Choudhary NS, Saigal S, Saraf N, et al. Outcome of living donor liver transplantation for Wilson’s disease in adults: a single center experience. J Clin Exp Hepatol. 2018;8:132–135.
Russell K, Gillanders LK, Orr DW, Plank LD. Dietary copper restriction in Wilson’s disease. Eur J Clin Nutr. 2018;72:326–331.
Lichtmannegger J, Leitzinger C, Wimmer R, et al. Methanobactin reverses acute liver failure in a rat model of Wilson disease. J Clin Invest. 2016;126:2721–2735.
Ong SY, Gurrin LC, Dolling L, et al. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial. Lancet Haematol. 2017;4:e607–e614.
Vanclooster A, van Deursen C, Jaspers R, et al. Proton pump inhibitors decrease phlebotomy need in HFE hemochromatosis: double-blind randomized placebo-controlled trial. Gastroenterology. 2017;153:678–680.
Adams PC. Epidemiology and diagnostic testing for hemochromatosis and iron overload. Int J Lab Hematol. 2015;37(suppl 1):25–30.
Kowdley KV. Iron overload in patients with chronic liver disease. Gastroenterol Hepatol (N Y). 2016;12:695–698.
Kawabata H. The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis. Int J Hematol. 2018;107:31–43.
Muckenthaler MU, Rivella S, Hentze MW, et al. A red carpet for iron metabolism. Cell. 2017;168:344–361.
Wang CY, Babitt JL. Liver iron sensing and body iron homeostasis. Blood. 2019;133:18–29.
Reichert CO, da Cunha J, Levy D, et al. Hepcidin: homeostasis and diseases related to iron metabolism. Acta Haematol. 2017;137:220–236.
Casu C, Nemeth E, Rivella S. Hepcidin agonists as therapeutic tools. Blood. 2018;131:1790–1794.
Brissot P, Cavey T, Ropert M, et al. Genetic hemochromatosis: pathophysiology, diagnostic and therapeutic management. Presse Med. 2017;46:e288–e295.
Sorensen E, Rigas AS, Didriksen M, et al. Genetic factors influencing hemoglobin levels in 15,567 blood donors: results from the Danish Blood Donor Study. Transfusion. 2019;59:226–231.
Grosse SD, Gurrin LC, Bertalli NA, et al. Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes. Genet Med. 2018;20:383–389.
Brissot P, Pietrangelo A, Adams PC, et al. Haemochromatosis. Nat Rev Dis Primers. 2018;4:1–15.
Kiely PD. Haemochromatosis arthropathy—a conundrum of the Celtic curse. J R Coll Physicians Edinb. 2018;48:233–238.
Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016;388:706–716.
Diez-L?pez C, Comin-Colet J, Gonz?lez-Costello J. Iron overload cardiomyopathy: from diagnosis to management. Curr Opin Cardiol. 2018;33:334–340.
Ganz T. Iron and infection. Int J Hematol. 2018;107:7–15.
Porto G, Brissot P, Swinkels DW, et al. EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). Eur J Hum Genet. 2016;24:479–495.
Elsayed ME, Sharif MU, Stack AG. Transferrin saturation: a body iron biomarker. Adv Clin Chem. 2016;75:71–97.
Golfeyz S, Lewis S, Weisberg IS. Hemochromatosis: pathophysiology, evaluation, and management of hepatic iron overload with a focus on MRI. Expert Rev Gastroenterol Hepatol. 2018;12:767–778.
Sandhu K, Flintoff K, Chatfield MD, et al. Phenotypic analysis of hemochromatosis subtypes reveals variations in severity of iron overload and clinical disease. Blood. 2018;132:101–110.
Palmer WC, Vishnu P, Sanchez W, et al. Diagnosis and management of genetic iron overload disorders. J Gen Intern Med. 2018;33:2230–2236.
Rombout-Sestrienkova E, van Kraaij MG, Koek GH. How we manage patients with hereditary haemochromatosis. Br J Haematol. 2016;175:759–770.
Pericleous M, Kelly C. The clinical management of hereditary haemochromatosis. Frontline Gastroenterol. 2018;9:110–114.
Hider RC, Hoffbrand AV. The role of deferiprone in iron chelation. N Engl J Med. 2018;379:2140–2150.
Труды отечественных авторов при подготовке статей по терапии для пользователей сайта - не использовались, так как их вы всегда можете найти в библиотеках.
